Actelion Pharmaceuticals Ltd.

GPTKB entity

Predicate	Object
gptkbp:instance_of	gptkb:Company
gptkbp:bfsLayer	4
gptkbp:bfsParent	gptkb:Actelion
gptkbp:acquired	gptkb:Johnson_&_Johnson
gptkbp:acquisition	January 2017
gptkbp:ceo	gptkb:Martine_Clozel
gptkbp:dissolved	gptkb:2017
gptkbp:employees	approximately 2,000
gptkbp:established	gptkb:1997
gptkbp:founded	gptkb:1997
gptkbp:founder	gptkb:Jean-Paul_Clozel
gptkbp:headquarters	gptkb:Allschwil,_Switzerland
https://www.w3.org/2000/01/rdf-schema#label	Actelion Pharmaceuticals Ltd.
gptkbp:industry	gptkb:Company
gptkbp:key_people	gptkb:David_E._Stump gptkb:Robert_A._Hugin gptkb:Michael_A._Houghton gptkb:Jean-Paul_Clozel gptkb:Martine_Clozel
gptkbp:location	gptkb:Switzerland
gptkbp:parent_company	gptkb:Johnson_&_Johnson
gptkbp:partnership	gptkb:GSK gptkb:temple gptkb:Takeda_Pharmaceutical_Company gptkb:Sanofi gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Merck_&_Co. gptkb:Roche gptkb:Amgen gptkb:Eli_Lilly_and_Company gptkb:Abb_Vie gptkb:Celgene gptkb:Novartis
gptkbp:products	gptkb:Bosentan gptkb:Epoprostenol gptkb:Iloprost gptkb:Macitentan gptkb:Selexipag gptkb:Treprostinil gptkb:Opsumit gptkb:Tracleer gptkb:Uptravi
gptkbp:research_focus	oncology rare diseases central nervous system disorders cardiovascular diseases infectious diseases metabolic diseases
gptkbp:revenue	$2.1 billion (2016)
gptkbp:specializes_in	pulmonary arterial hypertension
gptkbp:subsidiary	gptkb:Actelion_Pharmaceuticals_US,_Inc.
gptkbp:traded_on	gptkb:Swiss_Stock_Exchange
gptkbp:website	www.actelion.com